GlassScriptPhysician profile
Margaret Hovda
NPI 1376744581
$178,703.72
in general payments reported to CMS, 2019-2025
36 companies · $44K in 2025
The $44K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $46.31 · 2021: $15K · 2022: $26K · 2023: $50K · 2024: $44K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $93K · Honoraria: $20K · Travel and Lodging: $15K · Food and Beverage: $8,348 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $93,289.98 |
| Honoraria | $20,000.00 |
| Travel and Lodging | $15,476.43 |
| Food and Beverage | $8,347.95 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $173,836.73 | 2019-2025 | Inspire |
| Zoll Respicardia, INC. | $1,454.23 | 2022-2025 | Remede System |
| Astrazeneca Pharmaceuticals LP | $671.41 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $470.61 | 2019-2025 | Trelegy Ellipta, Nucala |
| Actelion Pharmaceuticals US, INC. | $296.35 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Takeda Pharmaceuticals U.S.A., INC. | $183.98 | 2024-2025 | Glassia, Cuvitru |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.63 | 2019-2025 | Ofev, Stiolto Respimat |
| Amgen INC. | $133.09 | 2024-2025 | Tezspire |
| Genentech USA, INC. | $124.49 | 2019 | |
| Philips North America LLC | $120.56 | 2019-2024 | (Ak6) Vest Therapy |
| Abiomed | $117.61 | 2019 | |
| Inogen, INC. | $111.04 | 2023-2025 | Inogen |
| Merck Sharp & Dohme LLC | $104.70 | 2024-2025 | Keytruda, Winrevair |
| Harmony Biosciences LLC | $99.15 | 2020-2025 | |
| Pfizer INC. | $90.38 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $83.33 | 2024-2025 | |
| Grifols USA, LLC | $80.10 | 2024 | Prolastin-C Liquid, Xembify |
| Axsome Therapeutics, INC. | $76.04 | 2024-2025 | Sunosi |
| Intuitive Surgical, INC. | $62.96 | 2022 | |
| Pulmonx Corporation | $55.01 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Electromed, INC. | $53.65 | 2024-2025 | Smartvest |
| Ambu INC. | $34.18 | 2025 | |
| Mylan Specialty L.P. | $33.20 | 2023 | Yupelri |
| Insmed, INC. | $31.31 | 2025 | Arikayce |
| Adma Biomanufacturing LLC | $27.48 | 2025 | |
| Jazz Pharmaceuticals INC. | $22.55 | 2019 | |
| Mallinckrodt Hospital Products INC. | $22.14 | 2025 | Acthar |
| Paratek Pharmaceuticals, INC. | $21.65 | 2024 | Nuzyra |
| Regeneron Healthcare Solutions, INC. | $20.41 | 2024 | Dupixent |
| Fisher & Paykel Healthcare INC | $18.78 | 2024 | Fisher & Paykel Healthcare |
| Sunovion Pharmaceuticals INC. | $18.52 | 2019 | |
| Gc Biopharma USA, INC. | $18.46 | 2025 | Alyglo |
| Baxter Healthcare | $18.35 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Viatris Specialty LLC | $16.21 | 2025 | Yupelri |
| 3b Medical, INC. | $13.93 | 2025 | Luna |
| Allergan, INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Hovda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.